e Canadian Pediatric Imaging Platform (C-PIP): A platform to support research in child brain health
Summary
The Canadian Pediatric Imaging Platform (C-PIP) is studying how the brain develops using magnetic resonance imaging, also known as MRI. The project aims to learn more about how the brain changes across life. The project will also look at how conditions like concussion can disrupt the brain’s development. This project is a partnership between the Alberta Children’s Hospital and 2 other leading research centres in Canada. C-PIP will make it easier for researchers to share data between research sites in a secure way. This makes it possible for different researchers to use the same data to answer different questions.
Eligibility
Eligible ages: 0 to 18
Accepts healthy participants: Yes
Inclusion criteria:
-Infants, children, and adolescents from birth to 18 years of age.
Exclusion criteria:
-Infants, children, or adolescents with severe neurodevelopmental disabilities
-Infants, children, or adolescents that are not able to receive an MRI (e.g., have metal in their bodies or other contraindications)
Participate
Fill out the following form if you want to participate in this research
UCalgary Notice of Collection
The University of Calgary (UCalgary) respects your privacy and is
committed to ensuring the privacy of all students, staff, and community members. Your personal information is being
collected under the authority of section 4(c) of the Protection of Privacy Act (POPA). It will be collected, used
and disclosed for the purposes outlined in UCalgary’s
Notice of
Collection, Use and Disclosure of Personal Information and managed in accordance with UCalgary’s
Privacy
Management Program.
Your personal information may be input into automated systems to generate content or make decisions,
recommendations, or predictions. If you have questions regarding this notice or UCalgary’s collection,
use, or disclosure of your personal information, please contact
accessandprivacy@ucalgary.ca.
Additional information
Contact information
Dr. Signe Bray
Principal investigator:
Signe Bray
Clinical trial:
No
REB-ID:
REB22-1749